Biopolym. Cell. 2014; 30(5):349-357.
http://dx.doi.org/10.7124/bc.0008B1
Огляди
Молекулярні механізми багатосторонньої біологічної активності інтерлейкіну-7
1Сливка А. В., 2Окунєв О. В.
  1. Навчально-науковий центр «Інститут біології»
    Київського національного університету імені Тараса Шевченка
    вул. Володимирська, 64/13, Київ, Україна, 01601
  2. Інститут молекулярної біології і генетики НАН України
    вул. Академіка Заболотного, 150, Київ, Україна, 03680

Abstract

У результаті імунологічних досліджень останніх 25 років показано, що інтерлейкін-7 (ІЛ-7) є одним з найважливіших регуляторних цитокінів імунної системи. Він чинить значний вплив на розвиток, проліферацію і активацію імунних клітин, однак не належить до класичних цитокінів-активаторів, як, наприклад, ІЛ- 2, оскільки багато типів клітин потребують його присутності майже на всіх стадіях розвитку, а спектр його активностей є вражаючим. Цей огляд має на меті узагальнити численні дані щодо структури ІЛ-7, його біологічної активності і особливостей функціонування in vitro та in vivo. Основний акцент зроблено на шляхах сигнальної трансдукції ІЛ-7, які визначають долю Т- і В-клітин, а також деяких інших клітин, важливих для підтримання гомеостазу організму. Аналіз літератури цієї сфери, на нашу думку, не лише виявив низку питань, які наразі не мають відповідей, але й окреслив напрямки для майбутніх досліджень.
Keywords: цитокін, імунна система, сигнальна трансдукція, регуляція.
Повний текст: (PDF, англійською)

References

[1] Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Ouaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA. Interleukins, from 1 to 37, and interferon-?: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127(3):701-21.e1-70.
[2] Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A, Mosley B, March CJ, Urdal D, Gillis S. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature. 1988;333(6173):571-3.
[3] Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL, Mochizuki DY. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med. 1988;167(3):988-1002.
[4] Kroemer RT, Doughty SW, Robinson AJ, Richards WG. Prediction of the three-dimensional structure of human interleukin-7 by homology modeling. Protein Eng. 1996;9(6):493-8.
[5] Costello R, Imbert J, Olive D. Interleukin-7, a major T-lymphocyte cytokine. Eur Cytokine Netw. 1993;4(4):253-62.
[6] Appasamy PM. Interleukin-7: biology and potential clinical applications. Cancer Invest. 1993;11(4):487-99.
[7] Vudattu NK, Magalhaes I, Hoehn H, Pan D, Maeurer MJ. Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun. 2009;10(2):132-40.
[8] Wiles MV, Ruiz P, Imhof BA. Interleukin-7 expression during mouse thymus development. Eur J Immunol. 1992;22(4):1037-42.
[9] Sakata T, Iwagami S, Tsuruta Y, Teraoka H, Tatsumi Y, Kita Y, Nishikawa S, Takai Y, Fujiwara H. Constitutive expression of interleukin-7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line. J Leukoc Biol. 1990;48(3):205-12.
[10] Oosterwegel MA, Haks MC, Jeffry U, Murray R, Kruisbeek AM. Induction of TCR gene rearrangements in uncommitted stem cells by a subset of IL-7 producing, MHC class-II-expressing thymic stromal cells. Immunity. 1997;6(3):351-60.
[11] Madrigal-Estebas L, McManus R, Byrne B, Lynch S, Doherty DG, Kelleher D, O'Donoghue DP, Feighery C, O'Farrelly C. Human small intestinal epithelial cells secrete interleukin-7 and differentially express two different interleukin-7 mRNA Transcripts: implications for extrathymic T-cell differentiation. Hum Immunol. 1997;58(2):83-90.
[12] Heufler C, Topar G, Grasseger A, Stanzl U, Koch F, Romani N, Namen AE, Schuler G. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med. 1993;178(3):1109-14.
[13] Gutierrez-Ramos JC, Olsson C, Palacios R. Interleukin (IL1 to IL7) gene expression in fetal liver and bone marrow stromal clones: cytokine-mediated positive and negative regulation. Exp Hematol. 1992;20(8):986-90.
[14] Golden-Mason L, Kelly AM, Traynor O, McEntee G, Kelly J, Hegarty JE, O'Farrelly C. Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: implications for extrathymic T cell development. Cytokine. 2001;14(3):143-51.
[15] de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, A?t-Yahia S, Banchereau J, Liu YJ, Lebecque S, Caux C. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol. 1998;160(4):1666-76.
[16] Sorg RV, McLellan AD, Hock BD, Fearnley DB, Hart DN. Human dendritic cells express functional interleukin-7. Immunobiology. 1998;198(5):514-26.
[17] Kr?ncke R, Loppnow H, Flad HD, Gerdes J. Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction. Eur J Immunol. 1996;26(10):2541-4.
[18] Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL, Mochizuki DY. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med. 1988;167(3):988-1002.
[19] Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD, Davison BL. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med. 1994;180(5):1955-60.
[20] Schluns KS, Kieper WC, Jameson SC, Lefran?ois L. Interleukin-7 mediates the homeostasis of na?ve and memory CD8 T cells in vivo. Nat Immunol. 2000;1(5):426-32.
[21] Meier D, Bornmann C, Chappaz S, Schmutz S, Otten LA, Ceredig R, Acha-Orbea H, Finke D. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity. 2007;26(5):643-54.
[22] Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20(4):394-7.
[23] Vogt TK, Link A, Perrin J, Finke D, Luther SA. Novel function for interleukin-7 in dendritic cell development. Blood. 2009;113(17):3961-8.
[24] Ribeiro VS, Hasan M, Wilson A, Boucontet L, Pereira P, Lesjean-Pottier S, Satoh-Takayama N, Di Santo JP, Vosshenrich CA. Cutting edge: Thymic NK cells develop independently from T cell precursors. J Immunol. 2010;185(9):4993-7.
[25] Treanor LM, Zhou S, Janke L, Churchman ML, Ma Z, Lu T, Chen SC, Mullighan CG, Sorrentino BP. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med. 2014;211(4):701-13.
[26] Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, Singer A. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity. 2004;21(2):289-302.
[27] Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 2011;11(5):330-42.
[28] Venkitaraman AR, Cowling RJ. Interleukin 7 receptor functions by recruiting the tyrosine kinase p59fyn through a segment of its cytoplasmic tail. Proc Natl Acad Sci U S A. 1992;89(24):12083-7.
[29] Cosenza L, Gorgun G, Urbano A, Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal. 2002;14(4):317-25.
[30] Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk BA, Gimpel S, Cosman D, Dower SK, March CJ, Namen AE, et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell. 1990;60(6):941-51.
[31] Rose T, Lambotte O, Pallier C, Delfraissy JF, Colle JH. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009;182(12):7389-97.
[32] Rose T, Pillet AH, Lavergne V, Tamarit B, Lenormand P, Rousselle JC, Namane A, Th?ze J. Interleukin-7 compartmentalizes its receptor signaling complex to initiate CD4 T lymphocyte response. J Biol Chem. 2010;285(20):14898-908.
[33] Pillet AH, Lavergne V, Pasquier V, Gesbert F, Th?ze J, Rose T. IL-2 induces conformational changes in its preassembled receptor core, which then migrates in lipid raft and binds to the cytoskeleton meshwork. J Mol Biol. 2010;403(5):671-92.
[34] McElroy CA, Holland PJ, Zhao P, Lim JM, Wells L, Eisenstein E, Walsh ST. Structural reorganization of the interleukin-7 signaling complex. Proc Natl Acad Sci U S A. 2012;109(7):2503-8.
[35] Perna SK, Savoldo B, Dotti G. Genetic modification of cytotoxic T lymphocytes to express cytokine receptors. Methods Mol Biol. 2014;1139:189-200.
[36] Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Cell. 1999;97(2):271-81.
[37] Wickham J Jr, Walsh ST. Crystallization and preliminary X-ray diffraction of human interleukin-7 bound to unglycosylated and glycosylated forms of its alpha-receptor. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63(Pt 10):865-9.
[38] Stroud RM, Wells JA. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE. 2004;2004(231):re7.
[39] Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20(4):394-7.
[40] Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377(6544):65-8.
[41] Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN. Defective lymphoid development in mice lacking Jak3. Science. 1995;270(5237):800-2.
[42] Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 2004;15(6):435-55.
[43] Chou WC, Levy DE, Lee CK. STAT3 positively regulates an early step in B-cell development. Blood. 2006;108(9):3005-11.
[44] van der Plas DC, Smiers F, Pouwels K, Hoefsloot LH, L?wenberg B, Touw IP. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain. Leukemia. 1996;10(8):1317-25.
[45] Heltemes-Harris LM, Willette MJ, Vang KB, Farrar MA. The role of STAT5 in the development, function, and transformation of B and T lymphocytes. Ann N Y Acad Sci. 2011;1217:18-31.
[46] Mandal M, Powers SE, Ochiai K, Georgopoulos K, Kee BL, Singh H, Clark MR. Ras orchestrates exit from the cell cycle and light-chain recombination during early B cell development. Nat Immunol. 2009;10(10):1110-7.
[47] Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004;24(18):8037-47.
[48] Goetz CA, Harmon IR, O'Neil JJ, Burchill MA, Farrar MA. STAT5 activation underlies IL7 receptor-dependent B cell development. J Immunol. 2004;172(8):4770-8.
[49] Malin S, McManus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P, Strasser A, Busslinger M. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol. 2010;11(2):171-9.
[50] Isaksen DE, Baumann H, Zhou B, Nivollet S, Farr AG, Levin SD, Ziegler SF. Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoietin-mediated signal transduction. J Immunol. 2002;168(7):3288-94.
[51] Ingley E, Klinken SP. Cross-regulation of JAK and Src kinases. Growth Factors. 2006;24(1):89-95.
[52] Venkitaraman AR, Cowling RJ. Interleukin-7 induces the association of phosphatidylinositol 3-kinase with the alpha chain of the interleukin-7 receptor. Eur J Immunol. 1994;24(9):2168-74.
[53] Corcoran AE, Smart FM, Cowling RJ, Crompton T, Owen MJ, Venkitaraman AR. The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. EMBO J. 1996;15(8):1924-32.
[54] Fleming HE, Paige CJ. Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B cell transition via an ERK/MAP kinase-dependent pathway. Immunity. 2001;15(4):521-31.
[55] Suzuki H, Terauchi Y, Fujiwara M, Aizawa S, Yazaki Y, Kadowaki T, Koyasu S. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science. 1999;283(5400):390-2.
[56] Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal. 2010;3(134):ra60.
[57] Baracho GV, Miletic AV, Omori SA, Cato MH, Rickert RC. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23(2):178-83.
[58] Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 2004;15(2):177-82.
[59] Yasuda T, Sanjo H, Pag?s G, Kawano Y, Karasuyama H, Pouyss?gur J, Ogata M, Kurosaki T. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity. 2008;28(4):499-508.
[60] Zhang L, Camerini V, Bender TP, Ravichandran KS. A nonredundant role for the adapter protein Shc in thymic T cell development. Nat Immunol. 2002;3(8):749-55.
[61] Giles AJ, Bender TP, Ravichandran KS. The adaptor protein Shc plays a key role during early B cell development. J Immunol. 2009;183(9):5468-76.
[62] Hsu HC, Mountz JD. Metabolic syndrome, hormones, and maintenance of T cells during aging. Curr Opin Immunol. 2010;22(4):541-8.
[63] Hong C, Luckey MA, Park JH. Intrathymic IL-7: the where, when, and why of IL-7 signaling during T cell development. Semin Immunol. 2012;24(3):151-8.
[64] Patra AK, Avots A, Zahedi RP, Sch?ler T, Sickmann A, Bommhardt U, Serfling E. An alternative NFAT-activation pathway mediated by IL-7 is critical for early thymocyte development. Nat Immunol. 2013;14(2):127-35.
[65] Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472-84.
[66] Klingm?ller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 1995;80(5):729-38.
[67] Ortmann RA, Cheng T, Visconti R, Frucht DM, O'Shea JJ. Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation. Arthritis Res. 2000;2(1):16-32.
[68] Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995;14(12):2816-26.
[69] Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, Nicola NA. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A. 1998;95(1):114-9.
[70] Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89(9):3148-54.
[71] Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278(5344):1803-5.
[72] Heinrich PC, Behrmann I, M?ller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334 ( Pt 2):297-314.
[73] Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, Singer A. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity. 2004;21(2):289-302.
[74] Luo H, Charpentier T, Wang X, Qi S, Han B, Wu T, Terra R, Lamarre A, Wu J. Efnb1 and Efnb2 proteins regulate thymocyte development, peripheral T cell differentiation, and antiviral immune responses and are essential for interleukin-6 (IL-6) signaling. J Biol Chem. 2011;286(48):41135-52.
[75] Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood. 2010;115(16):3269-77.
[76] H?mar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol. 1995;129(1):55-64.
[77] Heaney ML, Golde DW. Soluble cytokine receptors. Blood. 1996;87(3):847-57.
[78] Janot-Sardet C, Assouline B, Cheynier R, Morre M, Beq S. A validated assay to measure soluble IL-7 receptor shows minimal impact of IL-7 treatment. J Immunol Methods. 2010;353(1-2):115-23.
[79] Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol. 2010;184(9):4679-87.
[80] Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res. 2011;17(11):3660-72.
[81] Boyman O, Ramsey C, Kim DM, Sprent J, Surh CD. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T Cell expansion without lymphopenia. J Immunol. 2008;180(11):7265-75.
[82] Lundstr?m W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL. Soluble IL7R? potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A. 2013;110(19):E1761-70.